Episode

E136: Secukinumab in PMR (REPLENISH)

Podcast
The Evidence Based Rheumatology Podcast
Published
Jun 15, 2026
Duration seconds
819
Processing state
not_requested
Canonical source
https://msputman.podbean.com/e/e136-secukinumab-in-pmr-replenish/
Audio
https://mcdn.podbean.com/mf/web/k8vibwq2e8x52wsh/e136.mp3
JSON
/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e136-secukinumab-in-pmr-replenish
Markdown
/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e136-secukinumab-in-pmr-replenish/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with. Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567